UNSPSC 51262007: Moxisylyte hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C16H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WK2KZM9V6X, chemically known as phenol, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)-, acetate (ester) but more generally known as moxisylyte hydrochloride, which bears US NIH Compound Identifier 4260. European Medicines Agency schedules Moxisylyte hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03343MIG.

UNSPSC 51262007 Moxisylyte hydrochloride is a Commodity code nominally for a specific pharmaceutical ingredient, but recent state and local activity under this code does not match the abstract category name. The two recent opportunities posted show solicitations for naloxone kits and drug deactivation systems (Seminole County, Florida) and a market-intelligence request regarding direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), neither of which involves moxisylyte hydrochloride as a procured item. The code appears to be a mislabeling artifact in state procurement systems rather than a reliable category for this specific pharmaceutical.

Activity under this code remains sparse and geographically scattered. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: deadline date predates posting date in source records). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a direct-to-manufacturer prescription program, but this request is exploratory market intelligence rather than a binding procurement. The mismatch between the code's nominal scope and actual solicitation content suggests that buyers should verify code assignments in formal opportunities before bidding, as the category does not reliably predict what pharmaceutical products or services state and local bodies are actually purchasing under this designation.